Search
Filters
Clear All
  • 12

Phase

  • 1
  • 1
  • 3
  • 6
  • 12
  • 1

Found 12 Pancreatitis trials

A listing of Pancreatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM)

E
Evan Fogel, MD
18-75 years
All genders
Researchers at Indiana University School of Medicine are conducting a study to find out how many people with acute pancreatitis develop diabetes. Diabetes is a known complication of acute pancreatitis. For some people, diabetes can last a few weeks after acute pancreatitis, but for others, it can appear a year or …
Learn More

Imaging Morphology of Pancreas in Diabetic Patients Following Acute Pancreatitis

T
Temel Tirkes, MD
18-75 years
All genders
What is this study about?This study aims to understand how often patients develop diabetes mellitus after acute pancreatitis and understand its clinical characteristics. It also aims to identify risk factors that predict the development of diabetes mellitus.
Learn More

Pancreatic Cyst Fluid Specimen Collection

M
Mohammad Al-Haddad, MD
18-100 years
All genders
Sponsor will receive de-identified leftover human pancreatic cyst fluid, which was collected according to the clinical sites’ standard of care. Pancreatic cysts are very common with the majority incidentally identified. There are several types of pancreatic cysts; some types can contain cancer or have malignant potential, whereas others are benign. …
Learn More

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (The PROCEED Study)

E
Evan Fogel, MD
18-65 years
All genders
This study will provide the most accurate and reliable estimates to date on disease progression and clinical events in evolving chronic pancreatitis. We also hope to develop from the results of this study some lab tests that will help us with early diagnosis of chronic pancreatitis and also to discover …
Learn More

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis (STTEPP)

E
Evan Fogel, MD
18-100 years
All genders
Phase 1
Interventional
The investigators propose to conduct a dose-escalation trial of an FDA-approved antiepileptic drug, lacosamide, added to opioid therapy in patients with chronic abdominal pain fromhronic pancreatitis (CP). This pilot trial will test the feasibility of the study design andvide reassurance regarding the tolerability and safety of lacosamide used concomitantly with …
Learn More

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

A
Anita Turk, MD
18-100 years
All genders
Phase 2
Interventional
This phase II trial investigates how well the addition of olaparib following completion ofurgery and chemotherapy works in treating patients with pancreatic cancer that has beenurgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2.b is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid …
Learn More

Phase II Randomized Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198

18-100 years
All genders
The purpose of this study is to find out what effects, good and/or bad, there are to adding the drug ramucirumab (RAM) to the usual chemotherapy regimen.
Learn More

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

A
Anita Turk, MD
18-100 years
All genders
Phase 2
Interventional
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor …
Learn More

Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable Unresectable or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region

R
Ryan Rhome, MD
18-100 years
All genders
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary cancers who have previously undergone treatment with chemotherapy, surgery, photodynamic therapy, conventionally fractionated radiation treatment, or any combination of these therapies.
Learn More

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18-100 years
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Learn More
1 - 10 of 12